today. afternoon on the Jaclyn, and to everyone Thanks, good call
positive report on that made progress results begin am we the with at Journey pleased we've in delivered Medical. I will QX. I that to the
by strong growth of million which This in in primarily products, revenues revenue a contributed versus two million During generated and ACCUTANE. represents QX over year. of last This we in X% the XX%. growth QBREXZA first was XXXX quarter These is XXXX. increase year-over-year million, period, of together, $XX $XX.X QX driven revenue the over of $X.X
Looking the and by when XX,XXX progress XXXX, QX showing grew compared by to compared TRxs. approximately at QBREXZA for XXXX, both X,XXX ACCUTANE to when prescriptions of prescriptions QX grew strong brands.
ACCUTANE the achieved and QBREXZA has of Trade through was share efforts both expanded expansion marketing Additionally, our and our respective prescriber This and of our Particularly our sales gained categories. Group. a of pharmacy reach and adoption their combination both brands market and by network. team in our Access with
is, expectation continue to Our for these remainder brands, grow XXXX. to the throughout of
quarter to that of able first XXXX in territories Our our strategic base significantly we XX SG&A the achieve to by territories in QX the profitability a our XX success. revenue evidenced with and to order performance business in XXXX. has versus reduce during This expenses X% achieve was during shown recently had most only pivot to were we growth be where profitability
make ZILXI, four infrastructure. performance QBREXZA, brands and our and these of XX% revenue, core our positive importantly, the commercial a during ACCUTANE, more given up Looking quarter: at brands AMZEEQ commercial optimized contribution than our the of generated
onetime products exception expenses from as the the these fee generated occurrences filing with have for DFD-XX. put, our NDA Simply surpassed revenues of our SG&A such
in of seasonality that quarter first quarter place throughout deductible as softest our typically take is as year. are insurance our well business QX resets as we Historically, affected by each the
with achieve an the the potential our expect took highlight sustained brands Looking DFD-XX. place our position future of from these and that incremental adjusted XXXX, from expense in cost growth EBITDA XXXX. as to further particularly our us of that optimization leverage into core believe we and expect reductions continue of dynamics ahead to a benefit basis business, additional on to result profitability anticipated launch We efforts
believe for Phase impending as over both our is inflammatory million for continue of treatment rosacea, to studies perspective, X% as a the macro the increase is for of X There preparing the approximately were III for as clinical best-in-class well success, total positive our the organization primary the States. endpoints, that our is for Assessment, with and which significant oral results growth Investigator a potential. provides are Global rosacea rosacea DFD-XX a an written of of shareholders. a is reduction XXXX, which with company both We patients suffer product XXXX. our there lesions XX.X were associated that launch In for the novel from From opportunity million The therapy on co-primary United IGA emphasis candidate. DFD-XX DFD-XX in over rosacea. trial prescriptions
that million We statistical XXXX. To for rosacea. had superiority color Oracea, in sales demonstrated TRx and placebo based a to in demonstrated and both our are is treatment DFD-XX as market from provide commonly rosacea. of the treat as standard care III opportunity take believe $XXX market-leading clinical Oracea to there efficacy, trials, current DFD-XX from in on market superior annual Phase share well topical other Oracea prescribed DFD-XX to oral that as opportunity, over significant around treatments
associated patient clinical can reduce Phase product believe profile, and DFD-XX's that or result clinical III significantly to prescriber We approved is accelerate ability trials the adoption. demonstrated help meaningful rosacea. differentiate can the this redness both erythema with DFD-XX a if our from Additionally, skin and
two prescribers that results, conducted safety results safety similar with second a with the adoption placebo. of on treatments we set of were rosacea the a sets tolerability Favorable include The full groups: feedback report payers and erythema DFD-XX likelihood to of inflammatory head-to-head majority DFD-XX Phase in DFD-XX, was as compared to by versus both plans fresh participants. conducted Oracea measure of reducing survey well was responses placebo. on demonstrated when which of completed a willingness versus driven that and favorable also focused positive for score Based First round statistical recently am reduction clinical on and that insurance of DFD-XX survey the I for DFD-XX; their lesions success assessment measure formulary. was IGA were commercial the in III pleased profile to as significant market statistical results critical superiority represent that a clinicians a of their research, of of trial of to
internal an DFD-XX of out prescribers adoption to successful rate in an to this care overwhelmingly exceeded This confidence Health high of our patients translates the prescriptions into at confirm own and astoundingly industry, us gives even XX%. approximate their adopt a DFD-XX. going prescribe rate and an willingness the X launch. for is rosacea and rate XX rosacea expectations DFD-XX In our
million captured million Given the makes States rosacea our the XX.X annually, adoption more United rate and sufferers even us over excited written research DFD's market prescriber in about market in X the potential. prescriptions
GPOs the are million With all contract shows results, for coverage not over for PBMs, to care respect to organizations research if market most, other likely lives. to XXX DFD-XX data payer almost and managed the with us provide
and a be is market payers will have research, inclusion are even confident approved. with will after result and of formulary for among As we DFD-XX high prescribers more this negotiations acceptance reimbursement that favorable that DFD-XX
in XX, FDA the application the us timelines for key process November accepted January was submitted our the whereby later QX, launch and We prelaunch regulatory by plans, provide To drug activities positioning we X activities on on recap PDUFA will DFD-XX new FDA application pricing DFD-XX. X, details provided we year our finalize for and the with product on additional date as on the review of this and a year. of March in of
trial program, Given the PDUFA impressive that the and efficacy III FDA remain head-to-head we approval highly confident data will us generated an provide by from the safety DFD with clinical date. Phase
Book have patents XXXX. We to robust provide exclusivity patent Regarding Orange intellectual has listable property, X DFD-XX a profile. currently until
result, the future. a generic having exclusivity market As without intrusion anticipate we foreseeable for
superior To the company DFD-XX, conclude the well and results we for discussion believe which our the enhance treatment pave of significantly rosacea bring will dermatology of and the new as paradigm, value the of prescribers value way we alike. as patients a that safety efficacy on to our would achievement
efforts. business development our into Moving
enhance into XXXX, interested with evaluate capable $XX an outside in for company property of payment A rights opportunities out-licensing intellectual We primary the the value. certain continue million for to is to States. shareholder out-license and to our and companies to entered to technologies continue Asian to countries. the focus agreement a Maruho, upfront develop we in QBREXZA which resulted licensing United In commercialize and related
explore as DFD-XX. continue We ZILXI globally exploit to opportunities and will for well IP monetize AMZEEQ our QBREXZA, technologies as to and and
in us landscape commercial we footprint. into products regard, as directly products FDA-approved as can to would to infrastructure. dermatology that our priority opportunities late-stage candidates. That our our commercially acquire bring would this available or the to we first product prescription that survey be would commercial leverage for new Second, existing FDA-approved continue in-license well focused dermatology In allow product fit
minimal allow adding best serve would candidates both our bring patients. revenue late-stage opportunities needs to we or in more us As bottom a of strong in unmet there secondary product in to are believe and clinical trial one treatment that these where areas lines. investment evaluating additive results can in focus, we dermatology therapeutic Executing our on that have with we will continue infrastructure, top demonstrated
call that, results the to first review quarter Financial for will our our to Joe Officer, the Benesch, financial With turn XXXX. over now I Chief of
